anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The matrix band for dentistry by using filling therapy, comprises thin, flexible and translucent plastic foil body (11) with an inner surface and a metal grid structure (12) connected to an outer surface of the body, which is plastically deformable. The matrix band retains a desired shape as an assembly. The metal grid structure is integrated into the body, is applied on the outer surface, has a shape of net and is a perforated metal band. The structure comprises number of holes (14), through which the light falls on the plastic foil body and the filling. The holes are made of a metal foil laser. The matrix band for dentistry by using filling therapy, comprises thin, flexible and translucent plastic foil body (11) with an inner surface and a metal grid structure (12) connected to an outer surface of the body, which is plastically deformable. The matrix band retains a desired shape as an assembly. The metal grid structure is integrated into the body, is applied on the outer surface, has a shape of net and is a perforated metal band. The structure comprises number of holes (14), through which the light falls on the plastic foil body and the filling. The holes are made of a metal foil laser. The number and/or size of holes in the structure and/or in the material of the plastic foil are selected so that only light with pre-determined wavelength can penetrates through the matrix band for the filling. The metal grid structure is applied on the exterior surface of the plastic foil body by structured coating and is produced by vaporizing a plastic foil. The metal structure is provided with a light-permeable protective coating on the outer surface of the foil. The filling is dimensionally stable after decreasing the matrix band. An independent claim is included for a method for manufacturing a matrix band for the dentistry by using filling therapy.
This single dose, open label, balanced, randomized, two-treatment, two-period, two-sequence, crossover study was conducted to compare the relative bioavailability and pharmacokinetic characteristics of a newly developed formulation with a conventional formulation in healthy subjects.

For this, a single-center, randomized, single-dose, open-label, 2-way crossover study with a 21-day washout period was conducted in 22 healthy volunteers. Plasma samples for the analysis of donepezil were collected up to 240 h after drug administration. Participants received either reference or test drug formulation of 10 mg donepezil in the first period and the alternative formulation in the second period. Plasma concentrations of donepezil were determined by validated high-performance liquid chromatography coupled to tandem mass spectrometry detection. Pharmacokinetic parameters, including Cmax and AUC, were determined by noncompartmental analysis. Analysis of variance (ANOVA) was carried out using log-transformed Cmax and AUC, and the mean ratios and their 90% confidence intervals (CI) were calculated. According to regulatory requirements set forth by Korea and the US Food and Drug Administration, products meet the criteria for bioequivalence if the 90% CIs of the mean ratios for Cmax and AUC are within the range of 0.80 to 1.25.
The present invention includes a method for reducing viral, bacterial, protozoan, fungal and other parasitic contamination from a biological solution. Biological solutions include, but are not limited to, solutions comprising blood, a blood component, cell culture or a component of a cell culture. In accordance with the present invention, there is provided, a method of inactivating a pathogen in blood or blood product in a container, comprising contacting at least one of said blood, blood product and container with a composition of the present invention. In accordance with the present invention, there is provided, a medical device comprising at least a surface treated with an anti-pathogenic composition of the present invention or containing at least an anti-pathogenic composition of present invention. In accordance with the present invention, there is provided, an anti-pathogenic composition for use in disinfecting fluids and biological tissues and surfaces contaminated with fluids and/or biological tissues, which comprises an anti-pathogenic amount of at least one quaternary ammonium compound in association with an acceptable carrier. A preferred anti-pathogenic composition of the present invention further comprises a bisguanidine compound. In accordance with the present invention, there is provided a method for inhibiting in vitro or ex vivo infection or replication of human immunodeficiency virus in a biological fluid, comprising treating said biological fluid with an effective inhibiting amount of a bis-guanidine compound or a derivative thereof, and at least one quaternary ammonium compound in combination with a pharmaceutically carrier, such as DMSO.
At this institution, a mFOLFIRINOX regimen has been adopted for metastatic pancreatic cancer (MPC) patients and promising results obtained. The modification resulted in a significantly reduced prevalence of severe adverse events in MPC patients, whereas the OS and PFS were extended to 10.3m and 7.0m, respectively, which is similar to that for patients on a full-dose regimen. Therefore, the investigators further evaluated the efficacy of mFOLFIRINOX in LAPC patients. Here, investigators want to prospectively enroll LAPC patients who underwent preoperative therapy with mFOLFIRINOX from April 2014 and compared the surgical resectability and surgical morbidity/surgical mortality among patients with surgically resectable pancreatic cancer (RPC) or LAPC who underwent surgery alone retrospectively. For patients with LAPC, mFOLFIRINOX was administrated for several cycles until the optimal response was obtained and then patients were evaluated for surgery. Moreover, survival data, including OS and PFS, were determined.
The present disclosure provides contrast photoacoustic probes, and compositions comprising such probes, designed to non-invasively detect and monitor various disease states, or targets within a subject human or animal. The probes are designed to be optically excited in tissue, ultimately generating thermal energy, which is transformed into acoustic energy by the response of the aqueous environment in the subject to the thermal emissions. The acoustic energy (sound) can then be detected by suitably applied transducers and digitally transformed into images indicating the location of the probe in the subject. One aspect of the disclosure encompasses photoacoustic probes that comprise: a carbon nanotube and a plurality of dye molecules bound to the carbon nanotube. The probes may further comprise a targeting moiety for localizing the probe at the site of a specific target. Another aspect of the present disclosure encompasses methods of detecting a target in animal or human subject, comprising: delivering a photoacoustic probe to a subject, allowing the photoacoustic probe to selectively bind to a target of the subject; and illuminating the system with an optical energy absorbable by the photoacoustic probe to generate an acoustic signal; and detecting the acoustic signal, thereby detecting the target in the subject.
Fibromyalgia (FM) is a chronic disorder that involves chronic widespread musculoskeletal pain typically accompanied by fatigue, disordered sleep, cognitive complaints, psychological distress, and impairments in functioning. Treatments to date have been only partially effective and typically of modest benefit. Many persons with FM remain persistently dysfunctional and often disabled. This has given greater impetus for patients to seek complementary and alternative medicine (CAM) therapies. In this study, a variant of electroencephalograph (EEG) biofeedback known as Low Energy Neurofeedback System (LENS) will be used to reduce FM symptoms.

Participants in this study will be randomly assigned to receive either LENS or placebo for several sessions. The Fibromyalgia Impact Questionnaire will be used to assess participants at the end of the study and at the 3- and 6- month follow-up visits.
Patients receiving Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets should be given the following information:

  1. Patients should be advised that Acetaminophen, caffeine and dihydrocodeine bitartrate tablet may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  2. Patients should be advised to report adverse experiences occurring during therapy.
  3. Patients should be advised not to adjust the dose of Acetaminophen, caffeine and dihydrocodeine bitartrate tablet without consulting the prescribing professional.
  4. Patients should not combine Acetaminophen, caffeine and dihydrocodeine bitartrate tablet with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because additive effects may occur.
  5. Women of childbearing potential who become, or are planning to become, pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.
  6. Patients should be advised that Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.
PURPOSE:To obtain the titled soft capsule resistant to the change of the enteric dissolution property with time, the degradation of the content, etc., by dissolving gelatin in an alkaline aqueous solution of a film-forming substance soluble in alkali and insoluble in acidic state, encapsulating a drug component with said solution, and treating the capsule with an acid after drying. CONSTITUTION:Gelatin is dissolved in an alkaline aqueous solution of a film- forming substance soluble in alkaline state and insoluble at <=5 pH (e.g., alpha,beta- ethylenic unsaturated carboxylic acid copolymer, a polycarboxylic acid-modified cellulose derivative, etc.), a drug component is encapsulated with the aqueous solution of the encapsulation agent, the obtained soft capsule is dried and immersed in a solution of an acid of preferably 5-15wt% concentration at <=10 deg.C for about 3min, and the product is washed with water and dried to obtain the objective soft capsule. The amounts of gelatin and the film-forming substance are preferably 60-70% and 10-20%, based on the encapsulation agent, respectively. Preferably, the capsule is incorporated with 10-20% of a polyol such as sorbit, glycerol, etc. as a plasticizer.
PURPOSE:A cosmetic having improved adhesivity to the skin and elegant metallic luster, containing noble metal coated pigment obtained by coating the surface of mica having specific average particle diameter with gold, platinum, Pd, silver, etc., by chemical plating. CONSTITUTION:A cosmetic containing 0.1-95wt% noble metal coated pigment obtained by coating the surface of mica having 20-300mum average particle diameter with gold, platinum, Pd, silver, etc., by chemical plating. The cosmetic has improved beautifully reflecting properties of appearance, elegant metallic luster of characteristic noble metal and improved adhesivity to the skin and hair. In the chemical plating, aqueous suspension of mica powder pretreated for plating is prepared and a plating solution (noble metal, reducing agent and pH adjustor) is added to the suspension. The method completely contrary to a conventional method is applied. The pigment is further coated with silica to eliminate a feeling of physical disorder to the skin and to provide soft luster.
This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
The invention relates to a method for preparing Stachys floridana schuttl.exBenth. polysaccharide with antitumor activity by hot water lixiviation. The method comprises the following steps of: drying and pulverizing a Stachys floridana schuttl.exBenth.; degreasing with ethanol; lixiviating with hot water; centrifuging to obtain supernatant fluid; concentrating at a reduced pressure; depositing with ethanol; centrifuging to obtain deposited ethanol and acetone and washing the deposited ethanol and acetone in sequence; and drying to constant weight to obtain the Stachys floridana schuttl.exBenth. polysaccharide. Through an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method for analyzing the antitumor activity of the Stachys floridana schuttl.exBenth. polysaccharide, a fact that the Stachys floridana schuttl.exBenth. polysaccharide has obvious inhibiting capability on gastric cancer BGC-823 cell proliferation is discovered. The method disclosed by the invention has the advantages of mild extracting conditions, no damage to polysaccharide structure, low cost, environment friendliness, and the like. The prepared Stachys floridana schuttl.exBenth. polysaccharide has obvious antitumor activity, and therefore, the Stachys floridana schuttl.exBenth. polysaccharide has broad application prospect.
Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
Dealing with persistent epithelial defects (PEDs) of the cornea is a challenge for ophthalmologists, and surgical intervention is occasionally indicated for the management of recalcitrant cases that are unresponsive to medical therapy. Bandage contact lenses (BCLs), especially silicone-hydrogel CLs with high oxygen permeability and transmissibility, are useful for treating PEDs. Over the past several years, autologous serum eye drops (ASEs) are gaining popular and widespread acceptance as adjuvant therapy for various ocular surface disorders, including PEDs recalcitrant to standard medical therapies.The combination of BCLs and ASEs for PEDs treatment have also been reported with satisfactory results in a few small series' of PED patients. In this study, we will conduct a prospective interventional study to investigate the therapeutic effects of the combination of topical 20% ASEs and silicone-hydrogel CLs for recalcitrant PEDs, as well as to compare the recurrence of epithelial breakdown with or without continuous usage of autologous serum eye drops after CL removal. Patients with PEDs for more than 4 weeks without improvement despite previous conventional treatment were treated. Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks. PED healing rate and epithelial defect recurrence during a 3-month follow-up were evaluated.
A functional polymer micelle PM-TLK and a preparation method and application thereof belong to the field of nano biomedical materials. The micelle is composed of a degradable polycaprolactone-b-polyethylene glycol block copolymer (PCL-b-PEG) micelle and surface functionalized polypeptide (D) -TLKIVW. (D) TLKIVW can interact with Tau protein, but has strong hydrophobicity and is easy to aggregate under physiological conditions, and the effect is poor. PCL-b-PEG is a polymer with high biocompatibility and degradability, and also has better protein adsorption resistance and long blood circulation performance. The functionalized polymer micelle can be efficiently combined with Tau protein aggregates, inhibit Tau protein aggregation in vitro, prevent Tau protein aggregate seeds from being transmitted to nerve cells, and promote the degradation of the Tau protein aggregates by the polymer micelle-Tau complex. The polymer micelle improves the solubility and stability of the polypeptide, enhances the action capacity, has simple preparation process and has wide application prospect in the aspect of treating the Alzheimer disease.
In this study, we leveraged machine learning (ML) approach to develop and validate new assessment tools for predicting stroke and bleeding among patients with atrial fibrillation (AFib) and cancer. We conducted a retrospective cohort study including patients who were newly diagnosed with AFib with a record of cancer from the 2012-2018 Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The ML algorithms were developed and validated separately for each outcome by fitting elastic net, random forest (RF), extreme gradient boosting (XGBoost), support vector machine (SVM), and neural network models with tenfold cross-validation (train:test = 7:3). We obtained area under the curve (AUC), sensitivity, specificity, and F2 score as performance metrics. Model calibration was assessed using Brier score. In sensitivity analysis, we resampled data using Synthetic Minority Oversampling Technique (SMOTE). Among 18,388 patients with AFib and cancer, 523 (2.84%) had ischemic stroke and 221 (1.20%) had major bleeding within one year after AFib diagnosis. In prediction of ischemic stroke, RF significantly outperformed other ML models [AUC (0.916, 95% CI 0.887-0.945), sensitivity 0.868, specificity 0.801, F2 score 0.375, Brier score = 0.035]. However, the performance of ML algorithms in prediction of major bleeding was low with highest AUC achieved by RF (0.623, 95% CI 0.554-0.692). RF models performed better than CHA2DS2-VASc and HAS-BLED scores. SMOTE did not improve the performance of the ML algorithms. Our study demonstrated a promising application of ML in stroke prediction among patients with AFib and cancer. This tool may be leveraged in assisting clinicians to identify patients at high risk of stroke and optimize treatment decisions.
Patients allocated to this arm will receive a placebo that will be similar in form to sildenafil pills in the interventional arm. These doses will be scheduled every 8 hours and wil be administered orally por up to seven consecutive days.
Renal Toxicity   
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of ZIPSOR in patients with advanced renal disease. The renal effects of ZIPSOR may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating ZIPSOR. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of ZIPSOR [see Drug Interactions (7)]. Avoid the use of ZIPSOR in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If ZIPSOR is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia   
Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
Weight loss was a common adverse reaction in DALIRESP clinical trials and was reported in 7.5% (331) of patients treated with DALIRESP 500 mcg once daily compared to 2.1% (89) treated with placebo [see Adverse Reactions (6.1)]. In addition to being reported as adverse reactions, weight was prospectively assessed in two placebo-controlled clinical trials of one year duration. In these studies, 20% of patients receiving roflumilast experienced moderate weight loss (defined as between 5-10% of body weight) compared to 7% of patients who received placebo. In addition, 7% of patients who received roflumilast compared to 2% of patients receiving placebo experienced severe (>10% body weight) weight loss. During follow-up after treatment discontinuation, the majority of patients with weight loss regained some of the weight they had lost while receiving DALIRESP. Patients treated with DALIRESP should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, weight loss should be evaluated, and discontinuation of DALIRESP should be considered.
PURPOSE: To establish an animal model for in-stent restenosis (ISR) after postthrombotic iliac vein stent placement and characterize histopathological changes in tissue within the stented vein.
MATERIALS AND METHODS: Iliac vein thrombosis was induced using balloon occlusion and thrombin injection in 8 male Boer goats. Mechanical thrombectomy and iliac vein stent placement were performed 3 days after thrombosis induction. Restenosis was evaluated by venography and optical coherence tomography (OCT) at 1 and 8 weeks after stent placement, and stent specimens were taken for pathological examination after the animals were euthanized.
RESULTS: Thrombosis induction was successful in all 8 goats, with >80% iliac vein occlusion. After thrombus removal, OCT revealed considerable venous intimal thickening and a small number of mural thrombi. Neointimal hyperplasia with thrombus formation was observed in all goats 1 week after stent implantation; the degree of ISR was 15%-33%. At 8 weeks, the degree of ISR was 21%-32% in 3 goats, and stent occlusion was observed in 1 goat. At 1 week, the neointima predominantly consisted of fresh thrombi. At 8 weeks, proliferplastic fibrotic tissue and smooth muscle cells (SMCs) were predominant, and the stent surfaces were endothelialized in 2 of 3 goats and partially endothelialized in 1 goat.
CONCLUSIONS: In the goat model, postthrombotic neointimal hyperplasia in the venous stent may result from time-dependent thrombus formation and organization, accompanied by migration and proliferation of SMCs, causing ISR. These results provide a basis to further explore the mechanism of venous ISR and promote the development of venous stents that reduce neointimal hyperplasia.
All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.